696 related articles for article (PubMed ID: 17504843)
1. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.
Roddy E; Zhang W; Doherty M
Ann Rheum Dis; 2007 Oct; 66(10):1311-5. PubMed ID: 17504843
[TBL] [Abstract][Full Text] [Related]
2. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
[TBL] [Abstract][Full Text] [Related]
3. Casebook consults: improving outcomes in gout (multimedia activity).
Doghramji PP; Mandell BF; Pope RS
Am J Med; 2012 Aug; 125(8):S1. PubMed ID: 22840678
[TBL] [Abstract][Full Text] [Related]
4. Up-titration of allopurinol in patients with gout.
Jennings CG; Mackenzie IS; Flynn R; Ford I; Nuki G; De Caterina R; Riches PL; Ralston SH; MacDonald TM;
Semin Arthritis Rheum; 2014 Aug; 44(1):25-30. PubMed ID: 24560169
[TBL] [Abstract][Full Text] [Related]
5. GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations.
Goossens J; Lancrenon S; Lanz S; Ea HK; Lambert C; Guggenbuhl P; Saraux A; Delva C; Sahbane S; Lioté F
Joint Bone Spine; 2017 Jul; 84(4):447-453. PubMed ID: 28411137
[TBL] [Abstract][Full Text] [Related]
6. Hyperuricaemia and gout.
Shipley M
J R Coll Physicians Edinb; 2011 Sep; 41(3):229-33. PubMed ID: 21949921
[TBL] [Abstract][Full Text] [Related]
7. The current state of care in gout: Addressing the need for better understanding of an ancient disease.
Zychowicz ME; Pope RS; Graser E
J Am Acad Nurse Pract; 2010 Nov; 22 Suppl 1():623-36. PubMed ID: 21054636
[TBL] [Abstract][Full Text] [Related]
8. [Summary of the Dutch College of General Practitioners' "Gout" Standard].
Romeijnders AC; Gorter KJ
Ned Tijdschr Geneeskd; 2002 Feb; 146(7):309-13. PubMed ID: 11876034
[TBL] [Abstract][Full Text] [Related]
9. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
10. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Zhang W; Doherty M; Bardin T; Pascual E; Barskova V; Conaghan P; Gerster J; Jacobs J; Leeb B; Lioté F; McCarthy G; Netter P; Nuki G; Perez-Ruiz F; Pignone A; Pimentão J; Punzi L; Roddy E; Uhlig T; Zimmermann-Gòrska I;
Ann Rheum Dis; 2006 Oct; 65(10):1312-24. PubMed ID: 16707532
[TBL] [Abstract][Full Text] [Related]
11. Serum urate levels and gout flares: analysis from managed care data.
Sarawate CA; Patel PA; Schumacher HR; Yang W; Brewer KK; Bakst AW
J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538
[TBL] [Abstract][Full Text] [Related]
12. Opportunities for improving medication use and monitoring in gout.
Singh JA; Hodges JS; Asch SM
Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
14. Italian Society of Rheumatology recommendations for the management of gout.
Manara M; Bortoluzzi A; Favero M; Prevete I; Scirè CA; Bianchi G; Borghi C; Cimmino MA; D'Avola GM; Desideri G; Di Giacinto G; Govoni M; Grassi W; Lombardi A; Marangella M; Matucci Cerinic M; Medea G; Ramonda R; Spadaro A; Punzi L; Minisola G
Reumatismo; 2013 Mar; 65(1):4-21. PubMed ID: 23550256
[TBL] [Abstract][Full Text] [Related]
15. 2016 updated EULAR evidence-based recommendations for the management of gout.
Richette P; Doherty M; Pascual E; Barskova V; Becce F; Castañeda-Sanabria J; Coyfish M; Guillo S; Jansen TL; Janssens H; Lioté F; Mallen C; Nuki G; Perez-Ruiz F; Pimentao J; Punzi L; Pywell T; So A; Tausche AK; Uhlig T; Zavada J; Zhang W; Tubach F; Bardin T
Ann Rheum Dis; 2017 Jan; 76(1):29-42. PubMed ID: 27457514
[TBL] [Abstract][Full Text] [Related]
16. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
17. A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis.
Stuart RA; Gow PJ; Bellamy N; Campbell J; Grigor R
N Z Med J; 1991 Mar; 104(908):115-7. PubMed ID: 2011292
[TBL] [Abstract][Full Text] [Related]
18. [Hyperuricemia and gout--treatment].
Gröbner W; Walter-Sack I
Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
[No Abstract] [Full Text] [Related]
19. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Dalbeth N; Kumar S; Stamp L; Gow P
J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
[TBL] [Abstract][Full Text] [Related]
20. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia.
Hamburger M; Baraf HS; Adamson TC; Basile J; Bass L; Cole B; Doghramji PP; Guadagnoli GA; Hamburger F; Harford R; Lieberman JA; Mandel DR; Mandelbrot DA; McClain BP; Mizuno E; Morton AH; Mount DB; Pope RS; Rosenthal KG; Setoodeh K; Skosey JL; Edwards NL;
Postgrad Med; 2011 Nov; 123(6 Suppl 1):3-36. PubMed ID: 22156509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
